121 related articles for article (PubMed ID: 19605743)
1. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis.
Grabar PB; Rozman B; Logar D; Praprotnik S; Dolzan V
Ann Rheum Dis; 2009 Aug; 68(8):1367-8. PubMed ID: 19605743
[No Abstract] [Full Text] [Related]
2. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
Pawlik A; Herczynska M; Kurzawski M; Safranow K; Dziedziejko V; Drozdzik M
Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032
[TBL] [Abstract][Full Text] [Related]
3. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.
O'Doherty C; Schnabl M; Spargo L; Cleland LG; James M; Proudman SM; Wiese MD
Pharmacogenomics; 2012 Sep; 13(12):1427-34. PubMed ID: 22966891
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.
Soukup T; Dosedel M; Nekvindova J; Toms J; Vlcek J; Pavek P
Clin Exp Rheumatol; 2015; 33(3):426-32. PubMed ID: 25664505
[TBL] [Abstract][Full Text] [Related]
5. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis.
Ju JH; Kim SI; Lee JH; Lee SI; Yoo WH; Choe JY; Chung SH; Lee J; Lee YH; Lee SS; Yoon HJ; Yoon CH; Kim HY; Park SH
Arthritis Rheum; 2007 Jun; 56(6):2094-6. PubMed ID: 17530652
[No Abstract] [Full Text] [Related]
6. Macrophage activation syndrome after leflunomide treatment in an adult rheumatoid arthritis patient.
Ricci M; Rossi P; De Marco G; Varisco V; Marchesoni A
Rheumatology (Oxford); 2010 Oct; 49(10):2001. PubMed ID: 20601656
[No Abstract] [Full Text] [Related]
7. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
Bohanec Grabar P; Rozman B; Tomsic M; Suput D; Logar D; Dolzan V
Eur J Clin Pharmacol; 2008 Sep; 64(9):871-6. PubMed ID: 18496682
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide.
Martinez-Taboada VM; Rodriguez-Valverde V; Gonzalez-Vilchez F; Armijo JA
Rheumatology (Oxford); 2004 Nov; 43(11):1451-3. PubMed ID: 15501999
[No Abstract] [Full Text] [Related]
9. Mechanism of action of leflunomide in rheumatoid arthritis.
Fox RI
J Rheumatol Suppl; 1998 Jul; 53():20-6. PubMed ID: 9666414
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.
Wiese MD; Schnabl M; O'Doherty C; Spargo LD; Sorich MJ; Cleland LG; Proudman SM
Arthritis Res Ther; 2012 Jul; 14(4):R163. PubMed ID: 22784880
[TBL] [Abstract][Full Text] [Related]
11. Neuropathy associated with leflunomide: a case series.
Martin K; Bentaberry F; Dumoulin C; Longy-Boursier M; Lifermann F; Haramburu F; Dehais J; Schaeverbeke T; Bégaud B; Moore N
Ann Rheum Dis; 2005 Apr; 64(4):649-50. PubMed ID: 15769926
[No Abstract] [Full Text] [Related]
12. Leflunomide (Arava)-induced cystoid macular oedema.
Barak A; Morse LS; Schwab I
Rheumatology (Oxford); 2004 Feb; 43(2):246-8. PubMed ID: 14739469
[No Abstract] [Full Text] [Related]
13. Leflunomide-induced subacute cutaneous lupus erythematosus.
Goëb V; Berthelot JM; Joly P; Mejjad O; de Quatrebarbes J; Reynaud-Hautin C; Vittecoq O; Le Loët X
Rheumatology (Oxford); 2005 Jun; 44(6):823-4. PubMed ID: 15757964
[No Abstract] [Full Text] [Related]
14. Leflunomide-induced peripheral neuropathy.
Kho LK; Kermode AG
J Clin Neurosci; 2007 Feb; 14(2):179-81. PubMed ID: 17107800
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
Bao C; Chen S; Gu Y; Lao Z; Ni L; Yu Q; Xu J; Li X; Liu J; Sun L; He P; Ma J; Xu S; Ding C
Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
[TBL] [Abstract][Full Text] [Related]
16. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
[TBL] [Abstract][Full Text] [Related]
18. Peripheral neuropathy in patients on leflunomide.
Bharadwaj A; Haroon N
Rheumatology (Oxford); 2004 Jul; 43(7):934. PubMed ID: 15213340
[No Abstract] [Full Text] [Related]
19. Severe aplastic anaemia following leflunomide therapy.
Wüsthof M; Smirnova A; Bacher U; Kröger N; Zander AR; Schuch G; Bokemeyer C
Rheumatology (Oxford); 2010 May; 49(5):1016-7. PubMed ID: 20032226
[No Abstract] [Full Text] [Related]
20. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Upton RN; Foster DJ
Br J Clin Pharmacol; 2016 Jan; 81(1):113-23. PubMed ID: 26331989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
